Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Markers of Aging in Older Adults

The Effect of GLP1 Receptor Agonists on Physical Function, Body Composition, and Biomarkers of Aging in Older Overweight/Obese Adults With Insulin Resistance

Semaglutide is a medication approved by the US Food and Drug Administration (FDA) as an antihyperglycemic (a drug that reduces glucoses in those with diabetes) and for weight management. This new study will help find out what effects, semaglutide has on people who take the drug and the drug's effect on physical function, body composition, and aging.

Inclusion Criteria:

• Older than 65
• Have prediabetes or diabetes
• BMI ≥ 27.0 kg/m2
• Living independently (not in assisted living or nursing home)

Exclusion Criteria:

• Have heart disease
• Have liver disease
• Smoke